CASI Pharmaceuticals Doses First Patient In Phase 1/2 Clinical Trial Of CID-103 For Immune Thrombocytopenia

CASI Pharmaceuticals Inc -3.47%

CASI Pharmaceuticals Inc

CASI

2.50

-3.47%

CASI Pharmaceuticals Doses First Patient In Phase 1/2 Clinical Trial Of CID-103 For Immune Thrombocytopenia
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via